Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters

Drug safety in Canada: 2 steps forward, 1 step back

Beverley A. Orser, Claire Dionee and Sylvia Hyland
CMAJ January 03, 2006 174 (1) 66; DOI: https://doi.org/10.1503/cmaj.1050235
Beverley A. Orser
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claire Dionee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sylvia Hyland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Enhancement of patient safety has become a priority for health care practitioners and organizations. Adverse medication events remain a major concern, as drug error is a significant cause of adverse outcomes for hospital inpatients.1 Patients are particularly vulnerable to medication error during the perioperative period. The leading cause of malpractice suits for Canadian anesthesiologists is medication error, and misidentification of drugs is the most frequent underlying problem.2,3

Improved safety requires a team effort with a focus on patients' well- being.4 Thus, it is disturbing that AstraZeneca has marketed in Canada a product that fails to meet the minimum labelling standard set out in the Food and Drugs Act.

Bupivacaine is a potent, potentially lethal local anesthetic that is used for local infiltration and for spinal and epidural anesthesia. It is considerably more cardiotoxic than many other local anesthetics. The label on the bupivacaine Polyamp® ampoule sold by AstraZeneca does not include the generic name of the drug, but rather identifies the product only by the brand name, Sensorcaine (Fig. 1).5

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Polyamp® ampoules containing bupivacaine are labelled with the company's brand name, Sensorcaine, rather than the generic name, bupivacaine.

The Food and Drugs Act states that “the inner and outer labels of a drug shall show (i) the proper name, if any, of the drug which, if there is a brand name for the drug, shall immediately precede or follow the brand name in type not less than one-half the size of that of the brand name; (ii) if there is no proper name, the common name of the drug.” The act also specifies that “No person shall sell a drug that is not labelled as required by these Regulations.”6

Clearly, the Sensorcaine packaging does not meet these legal requirements. This situation raises several disturbing questions. Why would an international pharmaceutical firm design ampoule labels with an emphasis on marketing rather than patient safety? How could this product bypass scrutiny by Health Canada and be introduced into Canadian hospitals? Once the oversight was brought to the attention of AstraZeneca, why did the manufacturer not post warnings and apply additional adhesive labels to the ampoule until a new product, appropriately labelled, was available?

Physicians and health care providers must demand that the pharmaceutical industry “join the team” and make patient safety more important than marketing considerations.

REFERENCES

  1. 1.↵
    Baker GR, Norton PG, Flintoft V, et al. The Canadian adverse events study: the incidence of adverse events among hospital patients in Canada. CMAJ 2004;170 (11): 1678-86.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Orser BA, Byrick R. Anesthesia-related medication error: time to take action. Can J Anesth 2004; 51: 756-60.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Medication error is anesthetic practice: a survey of 687 practitioners. Can J Anesth 2001;48:139-46.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Kohn LT, Corrigan JM, Donaldson MS, editors. To err is human: building a safer health system. Washington: National Academy Press, Institute of Medicine; 2000.
  5. 5.↵
    Bupivacaine injection: check your supplies. ISMP Can Safe Bull 2005 Jul 21;5(5). Available: www.ismp-canada.org/download/ISMPCSB2005-05Bupivacaine.pdf (accessed 2005 Nov 28).
  6. 6.↵
    C.01.004 & C.01.003 The Food and Drugs Act, Part C, Drugs, Division 1, Dec 30, 2002. p. 396. Available: www.hc-sc.gc.ca/fn-an/alt_formats/hpfb-dgpsa/pdf/legislation/e_e-drugs.pdf (accessed 2005 Nov 28).
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 174 (1)
CMAJ
Vol. 174, Issue 1
3 Jan 2006
  • Table of Contents
  • Index by author
  • Canadian Adverse Reaction Newsletter (117-124)

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Drug safety in Canada: 2 steps forward, 1 step back
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Drug safety in Canada: 2 steps forward, 1 step back
Beverley A. Orser, Claire Dionee, Sylvia Hyland
CMAJ Jan 2006, 174 (1) 66; DOI: 10.1503/cmaj.1050235

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Drug safety in Canada: 2 steps forward, 1 step back
Beverley A. Orser, Claire Dionee, Sylvia Hyland
CMAJ Jan 2006, 174 (1) 66; DOI: 10.1503/cmaj.1050235
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • REFERENCES
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Hospital-at-home programs in Canada: challenges and pitfalls
  • Author response to “Pitfalls of analyzing perinatal outcomes by health care provider”
  • Pitfalls of analyzing perinatal outcomes by health care provider
Show more Letters

Similar Articles

Collections

  • Topics
    • Drugs: adverse reactions
    • Health services
    • Patient safety & quality improvement

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire